Imagine discovering that a loved one has leukemia, only to learn that the cost of treatment could plunge the family into overwhelming debt. This is not a hypothetical scenario from the United States but a harsh reality for Chris Sluman and his family in North Bay, Ontario. The culprit: an obscure government agency that few Canadians know about.
The Sluman Family's Ordeal
In January, Sluman was diagnosed with B-cell Acute Lymphoblastic Leukemia. His family soon discovered that the two most effective drugs for his condition cost tens of thousands of dollars per treatment round. These drugs offer survival rates in the 90th percentile with fewer side effects than traditional chemotherapy or bone marrow transplants. Although Health Canada has approved both drugs, Canada's Drug Agency (CDA) recommended that provinces not cover them, leaving Sluman without insurance support.
The first drug, Blina, costs an estimated $100,000 per 30-day cycle. Sluman needs five cycles, plus a $75,000 round of Ponatinib, bringing the total to a staggering $575,000. Initially, Sluman opted for chemotherapy, but a GoFundMe campaign raised enough for him to start the superior treatment. However, many Canadians are not so fortunate.
The Role of Canada's Drug Agency
Health Canada approves drugs for safety and efficacy, while the CDA advises provinces on coverage based on cost-effectiveness. Critics argue that the CDA acts as a bureaucratic middleman, delaying access to life-saving treatments. In Manitoba, Jeremy Bray faced a similar denial until political pressure forced the province to cover his medication. Sluman's case highlights a systemic issue: when the CDA deems drugs too expensive, provincial programs like Ontario's Drug Benefit refuse coverage, forcing patients to rely on charity or debt.
"If drugs are approved by Health Canada, the process should bypass the CDA entirely," says Jay Goldberg, Canadian affairs manager at the Consumer Choice Center. "The CDA serves no real purpose other than to deny Canadians access to cutting-edge drugs through bureaucratic delays."
The Need for Reform
Canadians deserve first-rate health care, but bureaucracy is undermining that promise. Patients like Sluman cannot afford to wait years for coverage decisions. They should not have to mortgage their futures or turn to GoFundMe for essential medications. The time for reform is now: eliminate unnecessary agencies like the CDA and ensure that once Health Canada approves a drug, it is covered by provincial plans without delay.
Goldberg emphasizes that this is not an isolated case. "For every Sluman, there are dozens of others who opt for less effective treatments because they cannot afford cutting-edge drugs, and because the CDA tells provinces to deny coverage." The solution lies in streamlining the approval-to-coverage process, putting patients' lives above bureaucratic cost concerns.
